Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Prior treatment

• Having been previously enrolled in this clinical trial
• Patients for whom systemic therapy is the most likely course regardless of PET findings.

Other illness

• Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial

Age

• Age: less than18 years

Other

• Contraindications to any of the ingredients of \[18F\]PSMA-1007
• Close affiliation with the investigational site
• At the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
• Being clinically unstable or requiring emergency treatment
• Patients who are unwilling to consider a biopsy if clinically recommended
• Patients who are unable to undergo a PET/CT scan

• Male with original diagnosis of adenocarcinoma of the prostate with prior definitive therapy
• Suspicion of recurrence or persistence
  • after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir (ASTRO-Phoenix)
  • after prostatectomy, PSA \> 0.2 ng/mL on 2 or more determinations (recurrence), or failure of PSA to fall to undetectable levels post-prostatectomy (persistence) (American Urological Association)
• For patients who previously had radical prostatectomy, salvage radiotherapy is one likely treatment plan; for patients who initially underwent radiotherapy (including brachytherapy), confirmation of low volume disease is needed to define (local) treatment.
• Life expectancy of 6 months or more as judged by the investigator
• Willing and able to undergo all study procedures
• Informed consent in writing